EQ Strangle Strategy

EQ (Equillium, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

EQ (Equillium, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $82.1M, a beta of 1.67 versus the broader market, a 52-week range of 0.27-2.7, average daily share volume of 429K, a public-listing history dating back to 2018, approximately 35 full-time employees. These structural characteristics shape how EQ stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.67 indicates EQ has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on EQ?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current EQ snapshot

As of May 15, 2026, spot at $2.21, ATM IV 116.70%, IV rank 20.28%, expected move 33.46%. The strangle on EQ below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on EQ specifically: EQ IV at 116.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a EQ strangle, with a market-implied 1-standard-deviation move of approximately 33.46% (roughly $0.74 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated EQ expiries trade a higher absolute premium for lower per-day decay. Position sizing on EQ should anchor to the underlying notional of $2.21 per share and to the trader's directional view on EQ stock.

EQ strangle setup

The EQ strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With EQ near $2.21, the first option leg uses a $2.32 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed EQ chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 EQ shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$2.32	N/A
Buy 1	Put	$2.10	N/A

EQ strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

EQ strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on EQ. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on EQ

Strangles on EQ are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the EQ chain.

EQ thesis for this strangle

The market-implied 1-standard-deviation range for EQ extends from approximately $1.47 on the downside to $2.95 on the upside. A EQ long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current EQ IV rank near 20.28% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on EQ at 116.70%. As a Healthcare name, EQ options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to EQ-specific events.

EQ strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. EQ positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move EQ alongside the broader basket even when EQ-specific fundamentals are unchanged. Always rebuild the position from current EQ chain quotes before placing a trade.

Frequently asked questions

What is a strangle on EQ?: A strangle on EQ is the strangle strategy applied to EQ (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With EQ stock trading near $2.21, the strikes shown on this page are snapped to the nearest listed EQ chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are EQ strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the EQ strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 116.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a EQ strangle?: The breakeven for the EQ strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current EQ market-implied 1-standard-deviation expected move is approximately 33.46%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on EQ?: Strangles on EQ are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the EQ chain.
How does current EQ implied volatility affect this strangle?: EQ ATM IV is at 116.70% with IV rank near 20.28%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.